ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics" or "the Company") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in
Late-breaking presentation will report long-term durability preclinical data for STX-1150, Scribe’s lead epigenetic silencing therapy for LDL cholesterol reduction now in clinical trials A second presentation will
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering
ALAMEDA, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies
ALAMEDA, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. ("Scribe Therapeutics") (NASDAQ:SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies
